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Despite the lack of sufﬁcient information on the safety of herbal products, their use as
alternative and/or complementary medicine is globally popular. There is also an increasing
interest in medicinal herbs as precursor for pharmacological actives. Of serious concern is
the concurrent consumption of herbal products and conventional drugs. Herb–drug inter-
action (HDI) is the single most important clinical consequence of this practice. Using a
structured assessment procedure, the evidence of HDI presents with varying degree of
clinical signiﬁcance.While the potential for HDI for a number of herbal products is inferred
from non-human studies, certain HDIs are well established through human studies and
documented case reports. Various mechanisms of pharmacokinetic HDI have been iden-
tiﬁed and include the alteration in the gastrointestinal functions with consequent effects
on drug absorption; induction and inhibition of metabolic enzymes and transport proteins;
and alteration of renal excretion of drugs and their metabolites. Due to the intrinsic phar-
macologic properties of phytochemicals, pharmacodynamic HDIs are also known to occur.
The effects could be synergistic, additive, and/or antagonistic. Poor reporting on the part of
patients and the inability to promptly identify HDI by health providers are identiﬁed as major
factors limiting the extensive compilation of clinically relevant HDIs. A general overview
and the signiﬁcance of pharmacokinetic and pharmacodynamic HDI are provided, detailing
basic mechanism, and nature of evidence available. An increased level of awareness of HDI
is necessary among health professionals and drug discovery scientists.With the increasing
number of plant-sourced pharmacological actives, the potential for HDI should always be
assessed in the non-clinical safety assessment phase of drug development process. More
clinically relevant research is also required in this area as current information on HDI is
insufﬁcient for clinical applications.
Keywords: Herb–drug interaction, traditional medicine, phytochemicals, transport proteins, cytochrome P450
INTRODUCTION
There is increasing consumptions of medicinal herbs and herbal
products globally, cutting across social and racial classes, as it
is observed both in developing and developed countries (Cheng
et al., 2002; Bodeker, 2007;Mitra, 2007). Medicinal plants were the
major agents for primary health care for many centuries before
the advent of modern medicine (Sheeja et al., 2006). Their use
however declined in most developed western countries during
the last century’s industrialization and urbanization (Ogbonnia
et al., 2008). In the past two decades however a new resurgence
in medicinal plants consumption was observed. According to the
WHO, about 70% of the world population currently uses medic-
inal herbs as complementary or alternative medicine (Wills et al.,
2000). It is estimated that over 40% of the adult American popula-
tion consume herbal products for one medical reason or the other
(Tachjian et al., 2010).A recent study involving 2055 patients in the
US also reveals that the consumption pattern of traditional med-
ications has no signiﬁcant gender or social difference (Kessler et al.,
2001). Consumption rate has also been particularly exponential in
Canada (Calixto, 2000),Australia (Bensoussan et al., 2004), as well
as Europe where the highest sales of herbal products have been
reported in Germany and France (Capasso et al., 2003). In Africa,
there is continuous addition to the list of medicinal herbs while
consumption rate is also increasing. Between 60 and 85% native
Africans use herbal medicine usually in combination (Van Wyk
et al., 2009).
The indications for herbal remedies are diverse as they are
employed in the treatment of a wide range of diseases (Ernst,
2005). Studies have shown that 67% of women use herbs for
perimenopausal symptoms, 45% use it in pregnancy, and more
than 45% parents give herbal medications to their children for
various medical conditions (Ernst, 2004). Regulations in most
countries do not require the demonstration of therapeutic efﬁ-
cacy, safety, or quality on the part of herbal remedies as most of
them are promoted as natural and harmless (Homsy et al., 2004;
Routledge, 2008). It is pertinent however, that herbs are not free
from side effects as some have been shown to be toxic (Déciga-
Campos et al., 2007; Patel et al., 2011). Recent study has shown
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habitual pattern of concomitant consumption of herbal and pre-
scriptionmedication. Kaufman et al. (2002) reported that 14–16%
of American adult population consume herbal supplements often
concomitantly with prescribed medications. Also, 49.4% of Israeli
consumers of herbal remedies use them with prescription drugs
(Giveon et al., 2004). This is signiﬁcant bearing in mind that less
than 40% of patients disclose their herbal supplement usage to
their health care providers coupled with the fact that many physi-
cians are unaware of the potential risks of herb–drug interactions
(HDI; Klepser et al., 2000).
HDI is one of the most important clinical concerns in the
concomitant consumption of herbs and prescription drugs. The
necessity of polypharmacy in the management of most diseases
further increases the risk of HDI in patients. The ability of
intestinal and hepatic CYP to metabolize numerous structurally
unrelated compounds, apart from being responsible for the poor
oral bioavailability of numerous drugs is responsible for the large
number of documented drug–drug and drug–food interactions
(Quintieri et al., 2008). This is more so, considering that oral drug
delivery is the most employed in the management of most disease
conditions in which case, drug interaction alters both bioavailabil-
ity and pharmacokinetic disposition of the drug. This alteration
and the resulting poor control of plasma drug concentrations
would particularly be of concern for drugs that have a narrow
therapeutic window or a precipitous dose–effect proﬁle (Aungst,
2000; Perucca, 2006). The risk of pharmacokinetic drug interac-
tion poses twomajor extremity challenges – pharmacotoxicity and
treatment failure. The former can result from the inhibition of the
metabolic enzymes responsible for the metabolism and clearance
of the drugs while the latter may be the consequence of enzymatic
induction leading to faster drug metabolism. This is in addition
to the intrinsic pharmacodynamic actions of the herbal products
themselves which may include potentiating, additive, antagonism,
or neutralization effects.
Until recently,HDIwas oftenunsuspectedbyphysicians for sev-
eral reasons. Most trained physicians lack adequate knowledge on
herbal drugs and their potentials for drug interactions (Clement
et al., 2005; Ozcakir et al., 2007; Fakeye and Onyemadu, 2008);
herbal products also vary considerably in compositions depending
on the source and package (Liang et al., 2004; Sousa et al., 2011);
most patients do not consider it necessary to disclose their herbal
consumptions to physicians who themselves hardly inquire such
(Cassidy, 2003;Howell et al., 2006;Chao et al., 2008;Kennedy et al.,
2008). Further challenges with herbal medications include scien-
tiﬁc misidentiﬁcation, product contamination and adulteration,
mislabeling, active ingredient instability, variability in collection
procedures, and failure of disclosure on the part of patients (Boul-
lata and Nace, 2000). A fairly recent systematic review by Izzo
and Ernst (2009) on the interactions between medicinal herbs and
prescribed medications provide some more details on these.
Herbal products are made of complex mixture of phar-
macologically active phytochemicals (Mok and Chau, 2006),
most of which are secondary metabolites generated through
the shikimate, acetate–malonate, and acetate–mevalonate path-
ways. These constituents include phenolics (such as tannins,
lignins, quinolones, and salicylates), phenolic glycosides (such as
ﬂavonoids, cyanogens, and glucosinolates), terpenoids (such as
sesquiterpenes, steroids, carotenoids, saponins, and iridoids), alka-
loids, peptides, polysaccharides (such as gums and mucilages),
resins, and essential oils which often contain some of the afore-
mentioned classes of phytochemicals (Wills et al., 2000; Wang
et al., 2008). This complexity increases the risk of clinical drug
interactions.
AIM, SEARCH STRATEGY, AND SELECTION CRITERIA
The current review was therefore aimed at providing an overview
of known and recently reported HDI with interest in the evi-
dence available and the mechanism thereof. The review was
systematically conducted by searching the databases of MED-
LINE, PUBMED, EMBASE, and COCHRAINE libraries for orig-
inal researches, and case reports on HDI using the following
search terms or combinations thereof: “drug–herb,” “herb–drug,”
“interaction,” “cytochrome P450,” “plant,” “extract,” “medicinal,”
“concomitant administration,” “herbal and orthodox medicines.”
Relevant search terms were employed to accommodate the vari-
ous individual medicinal herbs employed in Africa, America, Asia,
Europe, and Australia. The reported interactions and their mech-
anisms, with orthodox medications were searched and collated.
Searches were not limited by date or place of publications but to
publications available in English language.
RESULTS
CLINICAL PRESENTATION OF HERB–DRUG INTERACTIONS
Clinical presentations of HDI vary widely depending on the herbs
and the drugs concerned. Typical clinical presentation of HDI
include the potentiation of the effects of oral corticosteroids in the
presence of liquorice (Glycyrrhiza glabra; Liao et al., 2010); poten-
tiation of warfarin effects with resultant bleeding in the presence
of garlic (Allium sativum; Borrelli et al., 2007), dong quai (Angel-
ica sinensis; Nutescu et al., 2006), or danshen (Salvia miltiorrhiza;
Chan, 2001); decreased blood levels of nevirapine, amitriptyline,
nifedipine, statins, digoxin, theophylline, cyclosporine, midazo-
lam, and steroids in patients concurrently consuming St John’s
wort (SJW; Hypericum perforatum; De Maat et al., 2001; Hender-
son et al., 2002; Johne et al., 2002; Mannel, 2004; Borrelli and
Izzo, 2009), decreased oral bioavailability of prednisolone in the
presence of the Chinese herbal product xiao-chai-hu tang (sho-
saiko-to; Fugh-Berman, 2000); ginseng (Panax ginseng )-induced
mania in patients on antidepressants (Engelberg et al., 2001);
production of extrapyramidal effects as a result of the combi-
nation of neuroleptic drugs with betel nut (Areca catechu; Huang
et al., 2003; Coppola and Mondola, 2012); increased blood pres-
sure induced by tricyclic antidepressant-yohimbe (Pausinystalia
yohimbe) combination (Tam et al., 2001), increased phenytoin
clearance and frequent seizures when combined with Ayurvedic
syrup shankhapushpi (Patsalos and Perucca, 2003), among other
clinical manifestations. These clinical presentations depend on the
mechanism of HDI.
EVIDENCE-BASED HDI STUDIES AND CLINICAL RELEVANCE
Herb–drug interactions have been reported through various study
techniques. While these reports usually give evidence of potential
interactions, the level of evidence varies often failing to predict
the magnitude or clinical signiﬁcance of such HDI. Apart from
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the speciﬁc limitations attributable to study methods employed,
major draw-back in deducting relevant conclusions from reported
HDI include misidentiﬁcation and poor characterization of spec-
imen, presence and nature of adulterants (some of which may be
allergens), variations in study methodologies including extraction
procedures, source location of herbs involved, seasonal variation
in the phytochemical composition of herbal materials, under-
reporting and genetic factors involved in drug absorption, metab-
olism, and dynamics. Table 1 provides some limitations of the
study methods.
Recently, structured assessment procedures are emerging in an
attempt to provide levels of evidence for drug interactions. In
addition to evidence of interaction, such assessment take into con-
sideration clinical relevance of the potential adverse event resulting
from the interaction, the modiﬁcation- and patient-speciﬁc risk
factors, and disease conditions for which the interaction is impor-
tant. Van Roon et al. (2005) developed a system of hierarchical
evidence-based structured assessment procedure of drug–drug
interaction. This can be applicable to HDI. This method particu-
larly allows the extraction of HDIs that have been well established
and those that are merely inferred from certain phytochemical
characteristics. A modiﬁed form of this method as presented in
Table 2 is applied in this paper to provide the nature and level of
evidence for the HDIs mentioned.
MECHANISMS OF HERB–DRUG INTERACTIONS
The overlapping substrate speciﬁcity in the biotransformational
pathways of the physiologic systems is seen as the major reason for
drug–drug, food–drug, and HDI (Marchetti et al., 2007). The abil-
ity of different chemicalmoieties to interact with receptor sites and
alter physiological environment can explain pharmacodynamic
drug interactions while pharmacokinetic interactions arise from
altered absorption, interference in distribution pattern as well as
changes and competition in the metabolic and excretory pathways
(Izzo, 2005). The major underlying mechanism of pharmacoki-
netic HDI, like drug–drug interaction, is either the induction or
inhibition of intestinal and hepatic metabolic enzymes particu-
larly the CYP enzyme family. Additionally, similar effect on drug
transporters and efﬂux proteins particularly the p-glycoproteins in
the intestines is responsible in most other cases (Meijerman et al.,
2006; Nowack, 2008; Farkas et al., 2010). The pre-systemic activ-
ity of CYP and efﬂux proteins often inﬂuence oral bioavailability,
thus the modulating activity of co-administered herbal products
has been shown to result in pronounced reduction or increase in
the blood levels of the affected drugs (Brown et al., 2008).
Potential for in vivo drug interactions are often inferred from
in vitro studies with liver enzymes. The correlation of in vitro
results with in vivo behavior has yielded reliable results in cer-
tain cases in terms of in vivo predictability although the extent
of clinical signiﬁcant is poorly inferable (Rostami-Hodjegan and
Tucker, 2007; Iwamoto et al., 2008; Xu et al., 2009; Umehara and
Camenisch, 2011). Thus most of the well established HDIs, as
will be seen in subsequent sections, were initially demonstrated
through in vitro studies.
The interaction of herbal products with hepatic enzymes can
also result in pharmacodynamic effects (van den Bout-van den
Beukel et al., 2008; Nivitabishekam et al., 2009; Asdaq and Inam-
dar, 2010; Dasgupta et al., 2010; Kim et al., 2010a.) Speciﬁc liver
injury inducible by phytochemical agents includes elevation in
transaminases (Zhu et al., 2004; Saleem et al., 2010), acute and
chronic hepatitis (Stedman, 2002; Pierard et al., 2009), liver fail-
ure (Durazo et al., 2004), veno-occlusive disorders (DeLeve et al.,
2002), liver cirrhosis (Lewis et al., 2006), ﬁbrosis (Chitturi and
Farrell, 2000), cholestasis (Chitturi and Farrell, 2008), zonal or
diffusive hepatic necrosis (Savvidou et al., 2007), and steato-
sis (Wang et al., 2009). Mechanism of liver injury may include
bioactivation of CYP, oxidative stress, mitochondrial injury, and
apoptosis (Cullen, 2005).
Table 1 | Comparison of study methods available for HDI.
Report/study method Comments Advantages Limitations to clinical inferences
In vitro studies Deliberate investigations employing
metabolic enzymes, tissues, or
organs, e.g., CYP-transfected cell
lines, hepatic subcellular fractions,
liver slices, intestinal tissues
Provide information on potential
HDI, easy to perform, good for high
throughput screenings; Compared
to in vivo animal studies, results are
closer to human if human
liver-based technologies are
employed
Variations in experimental vs clinical concen-
trations; other in vivo phenomena like protein
binding and bioavailability are not accounted
for; poor reproducibility of results; poor corre-
lation to clinical situation
In vivo studies Involves metabolic studies in
mammals
Concentration and bioavailability of
active components are taken into
consideration
Results are often difﬁcult to interpret due to
species variation; use of disproportionate and
non-physiologic dosages
Case reports Patients diagnosed after history
taking, from HDI
Ideal in providing information on HDI Hardly discovered by physicians; infrequent
with poor statistical values in relation to each
medicinal herbs; under-reporting
Human studies Involves the use of human subjects The ideal study, providing directly
extrapolative data on interactions
Expensive; too stringent ethical considera-
tions; most subjects are healthy leaving out
the effects of pathologies on drug metabo-
lism; genetic variation in enzyme activity; poor
representative population
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Table 2 | Quality of HDI evidence for clinical risk assessment.
Level Description of evidence
1 Published theoretical proof or expert opinion on the possibility of HDI due to certain factors including the presence of known interacting
phytochemicals in the herbs, structure activity relationship
2 Pharmacodynamic and/or pharmacokinetic animal studies; in vitro studies with a limited predictive value for human in vivo situation
3 Well documented, published case reports with the absence of other explaining factors
4 Controlled, published interaction studies in patients or healthy volunteers with surrogate or clinically relevant endpoint
Induction and inhibition of metabolic enzymes
The CYP superfamily is generally involved in oxidative, peroxida-
tive, and reductive biotransformation of xenobiotics and endoge-
nous compounds (Nebert and Russell, 2002; Hiratsuka, 2011). It
is conventionally divided into families and subfamilies based on
nucleotide sequence homology (Fasinu et al., 2012). There is a
high degree of substrate speciﬁcity among the various families.
CYP belonging to the families 1, 2, and 3 are principally involved
in xenobiotic metabolism while others play a major role in the
formation and elimination of endogenous compounds such as
hormones, bile acids, and fatty acids (Norlin and Wikvall, 2007;
Amacher, 2010). The most important CYP subfamilies respon-
sible for drug metabolism in humans are 1A2, 2A6, 2C9, 2C19,
2D6, 2E1, 3A4, and 3A5 (Ono et al., 1996; Wang and Chou,
2010).
CYP1A1 and 1A2 are the two major members of the human
CYP1A subfamily. CYP 1A1 is mainly expressed in extra-hepatic
tissues such as the kidney, the intestines, and the lungs while
CYP1A2 constitutes about 15% of total hepatic CYP (Martignoni
et al., 2006). CYP2B6 is involved in drug metabolism while most
other members of the CYP2B subfamily play less signiﬁcant meta-
bolic roles (Pavek and Dvorak, 2008). The subfamily 2C is the
second most abundant CYP after 3A representing over 20% of the
total CYP present in the human liver. It comprises three active
members: 2C8, 2C9, and 2C19 all of which are also involved
in the metabolism of some endogenous compounds including
retinol and retinoic acid (Lewis, 2004). Few clinically relevant
drugs including paracetamol, chlorzoxazone, and enﬂurane are
metabolized by CYP2E1, the most active of the 2E subfamily
(Leclercq et al., 2000). CYP3A subfamily constitutes over 40%
of the total CYP in the human body (although the levels may
vary 40-fold among individuals) with CYP3A4 being the most
abundant of all isoforms highly expressed in the liver and the
intestines and participates in the metabolism of about half of
drugs in use today (Ferguson and Tyndale, 2011; Singh et al.,
2011). The speciﬁcity and selectivity of substrates and inhibitors
for these enzymes are particularly useful in pharmacokinetic and
toxicological studies.
Induction is the increase in intestinal and hepatic enzyme
activity as a result of increased mRNA transcription leading to
protein levels higher than normal physiologic values. When this
happens, there is a corresponding increase in the rate of drug
metabolism affecting both the oral bioavailability and the sys-
temic disposition. In the formulation and dosage design of oral
medications, allowance is often made for pre-systemic metabo-
lism in order to achieve predictable systemic bioavailability. A
disruption in this balance can result in signiﬁcant changes in blood
concentrations of the drugs. Certain herbal products have been
shown to be capable of inducing CYP. Concomitant administra-
tion of enzyme-inducing herbal products and prescription drugs
can therefore result in sub-therapeutic plasma levels of the latter
with therapeutic failure as a possible clinical consequence.
Apart from enzyme induction, herbal products can also inhibit
enzyme activities. The inhibition of CYP and other metabolic
enzymes is usually competitive with instantaneous and inhibitor
concentration-dependent effects (Zhang and Wong, 2005). Most
inhibitors are also substrates of CYP (Zhou, 2008). This phenom-
enon alters pharmacokinetic proﬁles of xenobiotics signiﬁcantly.
As a result of the suppression of the anticipated pre-systemic
intestinal and hepatic metabolism, unusually high plasma levels
of xenobiotics are observed. Toxic manifestation could be the
ultimate effect of this observation. An equally clinically impor-
tant consequence of enzyme inhibition is drug accumulation due
to subdued hepatic clearance. These effects will be of particu-
lar concerns in drugs with narrow therapeutic window or steep
dose–response proﬁles.
St John’s wort is one of the most widely used herbal antide-
pressants (Lawvere and Mahoney, 2005; Høyland, 2011). It is a
potent inducer of CYP3A4 and depending on the dose, dura-
tion and route of administration, it may induce or inhibit other
CYP isozymes and P-gp (Roby et al., 2000; Markowitz et al.,
2003b; Tannergren et al., 2004; Madabushi et al., 2006). Stud-
ies from case reports indicate that, due to its inducing effects
on CYP3A4, it signiﬁcantly reduces the plasma levels of CYP3A4
substrates including cyclosporine, simvastatin, indinavir,warfarin,
amitriptyline, tacrolimus, oxycodone, and nevirapine (Henderson
et al., 2002; Johne et al., 2002; Nieminen et al., 2010; Vlachojannis
et al., 2011). It has also been reported that the alteration in the
blood serum concentration of cyclosporine due to SJW has led to
organ rejection in patients (Ernst, 2002; Murakami et al., 2006).
Reports of breakthrough bleeding and unplanned pregnancies due
to interaction between SJW and oral contraceptives have also been
documented (Hu et al., 2005). The group of drugs with the highest
potential for clinically signiﬁcant pharmacokinetic drug interac-
tion with SJW is the antidepressants as SJW itself is consumed by
patients with depression. Its concomitant use with SSRI like ser-
traline and paroxetine has been reported to result in symptoms
of central serotonergic syndrome (Barbenel et al., 2000; Dannawi,
2002; Spinella and Eaton, 2002; Birmes et al., 2003; Bonetto et al.,
2007). It has also been said to increase the incidence of hypo-
glycemia in patients on tolbutamide without apparent alteration
in the pharmacokinetic proﬁle of tolbutamide (Mannel, 2004).
It also inhibits the production of SN-38, an active metabolite of
irinotecan, in cancer patients.
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Amitriptyline is a substrate to both CYP3A4 and intestinal P-
gp. The risk of therapeutic failure is thus high due to induction of
CYP3A4-dependent metabolism activities resulting in poor oral
bioavailability. In a study by Johne et al. (2002), a 21% decrease in
the area under the plasma concentration–time curve of amitripty-
linewas observed in 12depressedpatientswhowere concomitantly
administered with extracts of SJW and amitriptyline for 2weeks.
Other CYP and P-gp substrates whose pharmacokinetic pro-
ﬁle have been reportedly altered by SJW include anticoagulants
like phenprocoumon and warfarin; antihistamines like fexofena-
dine; antiretroviral drugs including protease inhibitors and reverse
transcriptase inhibitors; hypoglycemic agents such as tolbutamide;
immunosuppressants like cyclosporine, tacrolimus, andmycophe-
nolic acid; anticonvulsants such as carbamazepine; anti-cancer like
irinotecan; bronchodilators like theophylline; antitussive like dex-
tromethorphan; cardiovascular drugs like statins, digoxin, and
dihydropyridine calcium channel blockers; oral contraceptives;
opiates like methadone and loperamide; and benzodiazepines
including alprazolam and midazolam (Greeson et al., 2001; Di
et al., 2008; Hojo et al., 2011). Following a single dose adminis-
tration of 300mg standardized extracts of SJW containing 5%
hyperforin in humans, a maximum plasma concentration of
0.17–0.5μM hyperforin yielding a [I ]/K i> 0.22, in vivo extrap-
olation suggests a high possibility of in vivo pharmacokinetic
drug interaction (Agrosi et al., 2000). Bray et al. (2002) con-
ﬁrmed through animal studies that SJW modulates various CYP
enzymes. Dresser et al. (2007) demonstrated that SJW is capable
of inducing CYP3A4 in healthy subjects through the observation
of increased urinary clearance of midazolam. Thus animal and
human studies further conﬁrm SJW as containing both inhibitory
and inducing constituents on various CYP isozymes. These effects
may depend on dosage and duration of administration, and may
also be species- and tissue-speciﬁc. While the individual phyto-
chemical constituents of SJW have elicited varying effects on the
metabolic activity of the CYP isozymes, whole extracts and major
constituents especially hyperforin have been reported to inhibit
the metabolic activities of CYP1A2, 2C9, 2C19, 2D6, and 3A4 via
in vitro studies and in vivo studies (Lee et al., 2006; Madabushi
et al., 2006; Hokkanen et al., 2011).
Ginkgo biloba have been reported to induce CYP 2C19-
dependent omeprazole metabolism in healthy human subjects
(Yin et al., 2004). Piscitelli et al. (2002) in a garlic–saquinavir inter-
action study reported 51% decrease in saquinavir oral bioavail-
ability caused by the presence of garlic and attributable to garlic-
induced CYP3A4 induction. Its effects on the warfarin pharma-
cokinetic has also been reported in animal models (Taki et al.,
2012).
Although grapefruit juice is not consumed for medicinal pur-
poses, the discovery of the inhibitory activity of its ﬂavonoid
contents on CYP has led to further researches in medicinal herbs
whichhave revealedHDIpotentials inﬂavonoid-containingherbal
remedies (Choi and Burm, 2006; Palombo, 2006; Paine et al., 2008;
Quintieri et al., 2008; Alvarez et al., 2010). A related CYP inhibitor
is rotenone. By interfering with the electron transfer of the heme
iron, rotenone, a naturally occurring phytochemical found in sev-
eral plants such as the jicama vine plant is known to inhibit CYP
activity (Sanderson et al., 2004). Resveratrol, a natural polymer,
and tryptophan, an amino acid have been documented as potent
CYP inhibitors (Rannug et al., 2006). Some herbal medications
and their phytochemical constituents capable of interacting with
CYP are presented in Table 3. Amore detailed involvement of CYP
in HDI is detailed in some recently published reviews (Delgoda
and Westlake, 2004; Pal and Mitra, 2006; Cordia and Steenkamp,
2011; Liu et al., 2011).
Phase II metabolic enzymes including uridine diphosphoglu-
curonosyl transferase (UGT), N -acetyl transferase (NAT), glu-
tathione S-transferase (GST), and sulfotransferase (ST) catalyze
the attachment of polar and ionizable groups to phase I metabo-
lites aiding their elimination. While cytochrome P450-mediated
HDI have been extensively investigated in various studies, the
effects of herbal extracts on phase II enzymes have not been ade-
quately studied. However, there is sufﬁcient evidence in literature
to suggest the potentials of phase II enzymes to induce clinically
signiﬁcant HDI.
In a study carried out in rat models by Sheweita et al. (2002),
extracts of hypoglycemic herbs, Cymbopogon proximus, Zygophyl-
lum coccineum, and Lupinus albus reduced the activity of GST and
GSH. Curcumin, from Curcuma longa, an herbal antioxidant with
anti-inﬂammatory and antitumor properties increased the activ-
ity of GST and quinone reductase in the ddY mice liver (Iqbal
et al., 2003). Valerian, an herbal sleeping aid has also demon-
strated the potential of inducing HDI through the inhibition of
UGT. Up to 87% of inhibition of UGT activity by valerian extract
was reported in an in vitro study utilizing estradiol and morphine
as probe substrate (Alkharfy and Frye, 2007). Kampo, a tradi-
tional Japanese medicine made of a mixture of several medicinal
herbs has shown inhibitory effects on some phase II enzymes. In
an in vitro study by Nakagawa et al. (2009), nine out of 51com-
ponents of kampo medicine elicited more than 50% inhibition
of UGT2B7-mediated morphine 3-glucuronidation. In the same
study, extracts of kanzo (Glycyrrhizae radix), daio (Rhei rhizoma),
and keihi (Cinnamomi cortex) elicited more than 80% inhibition
of morphine AZT glucuronidation. This result agrees with Katoh
et al. (2009) who carried out similar studies on rhei, keihi, and
ogon (Scutellariae radix).
Apart from the well-known effects on Ginkgo biloba on CYP
enzymes as illustrated earlier, its extracts have demonstrated
potent inhibition of mycophenolic acid glucuronidation inves-
tigated in human liver and intestinal microsomes (Mohamed and
Frye, 2010).
In a study to investigate the inﬂuence of 18 herbal remedies on
the activity of human recombinant sulfotransferase 1A3 employ-
ing dopamine and ritodrine as substrates, extracts of grape seed,
milk thistle, gymnema, SJW, ginkgo leaf, banaba, rafuma, and
peanut seed coat showed potent inhibition with IC50 values lower
than putative gastrointestinal concentration (Nagai et al., 2009).
Similarly, Mohamed and Frye (2011b) reported the inhibition of
UGT1A4 by green tea derived epigallocatechin gallate; UGT 1A6
and UGT1A9 by milk thistle; UGT 1A6 by saw palmetto; and
UGT 1A9 by cranberry. A recent publication presents evidence of
potential HDI mediated by UGT (Mohamed and Frye, 2011a).
Certain phytochemicals including coumarin, limettin,
auraptene, angelicin, bergamottin, imperatorin, and
isopimpinellin have also been reported to be capable of inducing
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hepatic GST activities (Kleiner et al., 2008). While the clinical
signiﬁcance of these ﬁndings are yet to be determined, it is note-
worthy that phase II metabolic enzymes may play signiﬁcant roles
in HDIs.
Inhibition and induction of transport and efﬂux proteins
The ATP-binding cassette (ABC) family of drug transporters plays
signiﬁcant roles in the absorption, distribution, and elimination
of drugs. P-gp, the most studied member of this family is a 170-
kDa plasma glycoprotein encoded by the human MDRI gene. It
is constitutively expressed in a number of body tissues and con-
centrated on the apical epithelial surfaces of the bile canaliculi of
the liver, the proximal tubules of the kidneys, the pancreatic duc-
tal cells, the columnar mucosal cells of the small intestine, colon,
and the adrenal glands (Marzolini et al., 2004; Degorter et al.,
2012). It is actively involved in drug absorption and elimination
from the intestines the liver, kidneys, and the brain. Speciﬁcally
these proteins are involved in the processes of hepatobiliary, direct
intestinal, and urinary excretion of drugs and their metabolites
(Szakács et al., 2008). Thus, the modulation of P-gp, or competi-
tive afﬁnity as substrates for its binding sites by co-administered
herbs presents a potential for alteration in the pharmacokinetic
proﬁle of the drug.
Pharmacokinetic interaction occurs when herbal drugs inhibit
or decrease the normal activity level of drug transporters through
a competitive or non-competitive mechanism. Interactions can
also occur through the induction of transport proteins via the
increase of the mRNA of the relevant protein. Studies have iden-
tiﬁed a number of clinically important P-gp inhibitors including
phytochemicals – ﬂavonoids, furanocoumarins, reserpine, quini-
dine, yohimbine, vincristine, vinblastine among others (Krishna
and Mayer, 2001; Zhou et al., 2004; Patanasethanont et al., 2007;
Iwanaga et al., 2010; Eichhorn and Efferth, 2011; Yu et al., 2011).
Borrel et al. (1994) reported that mobile ionophores such as
valinomycin, nonactin, nigericin, monensin, calcimycin, and lasa-
locid inhibit the efﬂux of anthracycline by P-gp whereas channel-
forming ionophores such as gramicidin do not (Larsen et al.,
2000). A number of herbal products which interact with CYP also
have similar effects on transport proteins (Table 3). The trans-
port proteins are actively involved in the pharmacokinetics of
anti-cancer drugs and account for one of the well-known mecha-
nisms of multiple resistance of cancerous cells to chemotherapeu-
tic agents (Bebawy and Sze, 2008; Bosch, 2008; He et al., 2011).
The inﬂuence of some herbs on transport proteins is presented in
Table 4. Clinically relevant interactions between herbal medicine
and chemotherapeutic agents are detailed in a recent review byYap
et al. (2010).
Alteration of gastrointestinal functions
Besides their inﬂuence on the intestinal metabolic enzymes and
efﬂux proteins,herbalmedications can alter the absorption of con-
comitantly administered medicines through a number of mecha-
nisms. Changes in the gastrointestinal pH and other biochemical
factors can alter dissolution properties and the absorption of
pH-dependent drugs such as ketoconazole and itraconazole. Com-
plexation and chelation, leading to the formation of insoluble
complexes and competition at the sites of absorption especially
with site-speciﬁc formulations can greatly affect the absorption of
medicines. Anthranoid-containing plants – cassia (Cassia senna),
Cascara (Rhamnus purshiana), rhubarb (Rheum ofﬁcinale), and
soluble ﬁbers including guar gum and psyllium can decrease drug
absorption by decreasing GI transit time. They are known to
increase GIT motility. On concomitant use with prescribed med-
ication, signiﬁcant alteration in the absorption of the latter has
been reported due to decreased GI transit time (Fugh-Berman,
2000).
Table 4 | Influence of herbal products on transport proteins.
Drug transporter Anti-cancer substrates Interacting herbal products LE Reference
P-glycoprotein
(ABCB-1, MDR-1)
Actinomycin D, daunorubicin, docetaxel,
doxorubicin, etoposide, irinotecan, mitoxantrone,
paclitaxel, teniposide, topotecan, vinblastine,
vincristine, tamoxifen, mitomycin C, tipifarnib,
epirubicin, bisantrene
Rosmarinus ofﬁcinalis 2 Oluwatuyi et al. (2004),
Nabekura et al. (2010)
MRP-1 (ABCC-1) Etoposide, teniposide, vincristine, vinblastine,
doxorubicin, daunorubicin, epirubicin, idarubicin,
topotecan, irinotecan, mitoxantrone, chlorambucil,
methotrexate, melphalan
Curcuma longa 2 Shukla et al. (2009)
MRP-2 (ABCC-2) SN-38G (metabolite of irinotecan), methotrexate,
sulﬁnpyrazone, vinblastine




etoposide, lurtotecan, mitoxantrone, SN-38,
topotecan
Flavonoid-containing herbs such as
Glycine max (soybean), Gymnema
sylvestre, and Cimicifuga racemosa
(black cohosh)
2 Merino et al. (2010),
Tamaki et al. (2010)
LE, level of evidence.
ABC,ATP-binding cassette; BCRP, breast cancer resistance protein;MDR,multidrug resistance gene;MRP,multidrug resistance-associated protein;MXR,mitoxantrone
resistance-associated protein.
www.frontiersin.org April 2012 | Volume 3 | Article 69 | 7
Fasinu et al. Herb–drug interactions
Table 5 | Some herbal remedies capable of interacting with other drugs via alteration in renal functions.
Medicinal plants Brief description Mechanism LE Reference
Aristolochia fangchi Chinese slimming herbal
remedy
Aristolochic acid content forms DNA
adducts in renal tissues leading to
extensive loss of cortical tubules
4 Lai et al. (2010)
Djenkol bean (Pithecellobium lobatum) Pungent smelling edible fruit,
used for medicinal purposes
in Africa
Contains nephrotoxic djenkolic acid 3 Luyckx and Naicker
(2008),Markell (2010)
Impila (Callilepis laureola) Popular South African
medicinal herb
Causes damage to the proximal convoluted




Wild mushrooms Widely consumed in Africa Some species especially Cortinarius
contains nephrotoxic orellanine
3 Wolf-Hall (2010)
Licorice root (Glycyrrhiza glabra) Leguminous herb native to
Europe and Asia, root and
extracts are used in chronic
hepatitis and other ailments
Contains glycyrrhizic acid whose
metabolite, glycyrrhetinic acid inhibits renal
11-hydroxysteroid dehydrogenase leading to
a pseudoaldosterone-like
effect – accumulation of cortisol in the
kidney, stimulation of the aldosterone
receptors in cells of the cortical leading to
increased BP, sodium retention, and
hypokalemia. This may potentiate the action
of drugs such as digoxin
4 Isbrucker and Bur-
dock (2006), Kataya
et al. (2011)
Noni fruit (Morinda citrifolia), alfalfa
(Medicago sativa), Dandelion (Taraxacum
ofﬁcinale), horsetail (Equisetum arvense),
stinging nettle (Urtica dioica)
These plants and their
extracts are used variously in
traditional medicine, and have
been shown to contain very
high potassium levels
Hyperkalemic, hepatotoxic 3 Saxena and Panbo-
tra (2003), Stadlbauer
et al. (2005), Jha
(2010)
Rhubarb (Rheum ofﬁcinale) Used as laxative High oxalic acid content may precipitate
renal stone formation and other renal
disorders
1 Bihl and Meyers
(2001)
Star fruit (Averrhoa carambola) A tree popular in Southeast
Asia and South America
employed traditionally as
antioxidant and antimicrobial
Oxalate nephropathy Chen et al. (2001),
Wu et al. (2011)
Uva ursi (Arctostaphylos uva ursi ),
goldenrod (Solidago virgaurea), dandelion
(Taraxacum ofﬁcinale), juniper berry
(Juniperus communis), horsetail
(Equisetum arvense), lovage root
(Levisticum ofﬁcinale), parsley
(Petroselinum crispum), asparagus root
(Asparagus ofﬁcinalis), stinging nettle leaf
(Urtica dioica), alfalfa (Medicago sativa)
Various plants used as
diuretics
Plants have diuretic property1 and may
increase the renal elimination of other drugs
1 Dearing et al. (2001),
Wojcikowski et al.
(2009)
LE, level of evidence.
1Some of these herbs exert their diuretic effects via extra-renal mechanisms with no direct effects on the kidneys (see Dearing et al., 2001).
Izzo et al. (1997) demonstrated that anthranoids could be
harmful to the gut epithelium by inhibiting Na+/K+ ATPase and
increasing the activity of nitric oxide synthase. This signiﬁcantly
increased intestinal transit due to the alteration in the intestinal
water and salt absorption and the subsequent ﬂuid accumulation.
In a study conducted by Munday and Munday (1999), a garlic-
derived compound was shown to increase the tissue activities of
quinone reductase and glutathione transferase in the gastroin-
testinal tract of the rat. In view of their roles in metabolism, both
enzymes are considered chemoprotective especially from chemical
carcinogens. In addition to CYP and P-gp mediated mechanisms,
the well-known ginseng-induced pharmacokinetic HDI may also
be due to its gastrointestinal effects especially its inhibitory effects
on gastric secretion (Suzuki et al., 1991). The potential of rhein and
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danthron to increase the absorption of furosemide, a poorly water-
soluble drug, has been demonstrated through in vitro studies
(Laitinen et al., 2007). In a study carried out on mice, a Chi-
nese herbal plant, Polygonum paleaceum, showed the potential to
depress the motility of the gastrointestinal tract, inhibit defeca-
tion reﬂex and delay gastric emptying (Zhang, 2002). A similar
study demonstrated the inhibitory effects of two Chinese tradi-
tional herbal prescriptions, Fructus aurantii immaturus and Radix
paeoniae alba on gastrointestinal movement (Fang et al., 2009).
The absorption of drugs such as phenoxymethylpenicillin,met-
formin, glibenclamide, and lovastatin may be reduced by high-
ﬁber herbal products through the sequestration of bile acids
(Colalto, 2010). Mochiki et al. (2010) reported the ability of
Kampo, a traditional Japanese medicine, to stimulate elevated
intestinal blood ﬂow, and to induce increased secretion of gas-
trointestinal hormones including motilin, vasoactive intestinal
peptide, and calcitonin gene-related peptide. Similarly, another
traditional Japanese medicine has been shown to increase the
intestinal secretion of ghrelin, a hunger-related hormone, lead-
ing to delayed gastric emptying (Tokita et al., 2007; Kawa-
hara et al., 2009; Hattori, 2010; Matsumura et al., 2010). Also,
Qi et al. (2007) demonstrated the capability of Da-Cheng-Qi-
Tang, a traditional Chinese herbal formula, to increase plasma
motilin, enhance gastrointestinal motility, improve gastric dys-
rhythmia, and reduce gastroparesis after abdominal surgery. These
effects have the potential of reducing the intestinal transit time
of concurrently administered drug, with the risk of reduced
absorption.
Alteration in renal elimination
This involves herbal products capable of interacting with renal
functions, leading to altered renal elimination of drugs. Such inter-
action can result from the inhibition of tubular secretion, tubular
reabsorption, or interference with glomerular ﬁltration (Isnard
et al., 2004). In addition to this group of herbal products are
those products consumed as diuretics. The mechanism of herbal
diuresis is complex and non-uniform. Certain herbs increase the
glomerular ﬁltration rate but do not stimulate electrolyte secretion
while someothers act as direct tubular irritants (Crosby et al., 2001;
Al-Ali et al., 2003). Some herbs capable of interacting with renal
functions and drug elimination are presented in Table 5.
Pharmacodynamic synergy, addition, and antagonism
Herb–drug interaction can occur through the synergistic or addi-
tive actions of herbal products with conventional medications as
a result of afﬁnities for common receptor sites (Ma et al., 2009).
This can precipitate pharmacodynamic toxicity or antagonistic
effects (Table 6). Like most other herbs, SJW contains complex
mixture of phytochemicals including phenylpropanes, naphtho-
danthrones, acylphloroglucinols, ﬂavonoids, ﬂavanol glycosides,
and biﬂavones. Hyperforin is known to inhibit the reuptake of
neurotransmitters (dopamine, serotonin, noradrenalin) and is
believed to be the bioactive responsible for the antidepressant
activity of SJW.
CONCLUSION
Concomitant use of herbs and conventional drugs may present
with untoward events. Evidence available in literature indicates
various mechanisms through which this can occur. By interacting
with conventional medication, herbal remedies may precipitate
manifestations of toxicity or in the other extreme, therapeutic
failure. A good knowledge of the potential of commonly con-
sumed herbal medicines to interact with prescription medicines,
irrespective of the nature of evidence available, will equip health
professionals in their practice. Apart from those demonstrated in
signiﬁcant number of human subjects, not all reported HDIs are
clinically signiﬁcant. As such, more clinically relevant research in
this area is necessary. This review provides information on com-
monly used herbs and their potentials for HDI within the levels of
evidence currently available.
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